The authors and journal apologise for an error in the above paper, which appeared in volume 31 part 7, article ID e240043. The error relates to a sentence in the Results section given on page 6.
The sentence stated:
“Twenty-three patients treated with pegvisomant developed secondary side effects: lipohypertrophy in 11, transaminases elevation in 2, asthenia in 2, abdominal discomfort in 2, hair loss in 1, and headache in 1.”
This should have stated:
“Nineteen patients treated with pegvisomant developed secondary side effects: lipohypertrophy in 11, transaminases elevation in 2, asthenia in 2, abdominal discomfort in 2, hair loss in 1, and headache in 1.”
The Version of Record has been corrected online.